Current Report Filing (8-k)
May 10 2017 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): May 10, 2017
Kiwa
Bio-Tech Products Group Corporation
(Exact
Name of Registrant as Specified in Charter)
Nevada
|
|
000-33167
|
|
77-0632186
|
(State
or Other Jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
Incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
310
N. Indian Hill Blvd., #702
Claremont,
California
|
|
|
|
91711
|
(Address
of Principal Executive Offices)
|
|
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (626) 715-5855
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR 240.13e-4(c)
|
TABLE
OF CONTENTS
Item
1.01 Entry into a Material Definitive Agreement.
On
May 9, 2017, Kiwa Bio-Tech Products Group Corporation (“Kiwa” or the “Company”) entered into a Convertible
Loan Agreement with Junwei Zheng wherein the lender agreed to advance of approximately US$ 4.5 million (RMB 30,000,000) under
a Convertible Promissory Note with a term of 24 months bearing interest at a rate of Fifteen Percent (15%) per annum. The Loan
is convertible into Common Stock at any time at the option of the Lender at a conversion price of $3.50 per share.
The
proceeds will be used for the further development of Kiwa products and distribution, as well as for general working capital.
Item
9.01 Financial Statements and Exhibits.
(d)
|
Exhibits
|
|
|
4.1
|
Convertible
Loan Agreement dated May 9, 2017 between Kiwa Bio-Tech Products Group Corporation and Junwei Zheng
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Dated:
May 10, 2017
|
Kiwa Bio-Tech Products Group Corporation
|
|
|
|
|
/s/
Yvonne Wang
|
|
By:
|
Yvonne
Wang
|
|
Title:
|
Chief
Executive Officer
|
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kiwa Bio Tech Products (CE) (USOTC:KWBT)
Historical Stock Chart
From Apr 2023 to Apr 2024